Skip to main content

Day: February 24, 2022

ARHT Media Announces Grant of Options and Board Change

TORONTO, Feb. 24, 2022 (GLOBE NEWSWIRE) — ARHT Media Inc. (“ARHT Media“) [TSXV:ART], the global leader in the development, production and distribution of high-quality, low latency hologram and digital content, announces today that it has granted an aggregate of 600,000 options to two directors pursuant to the Company’s stock option plan. The stock options vest in the following schedule: 1/3 immediately, 1/3 on the first anniversary of the grant; and 1/3 on the second anniversary of the grant, and may be exercised at a price of $0.245 for a period of five years from the date of grant. The grant of options is subject to the approval of the TSX Venture Exchange. ARHT would also like to announce the resignation of Kwok Hei (Benjamin) Yam from the board of directors. Larry O’Reilly said, “We would like...

Continue reading

Evoke Pharma and EVERSANA Announce Acceptance of Abstract for Poster of Distinction Presentation at Digestive Disease Week (DDW) May 2022

Revisiting the risk of tardive dyskinesia with metoclopramide use in diabetic gastroparesis: results of a real-world data driven epidemiology study SOLANA BEACH, Calif., and CHICAGO, Feb. 24, 2022 (GLOBE NEWSWIRE) — Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti (metoclopramide) nasal spray (GIMOTI), today announced that the results of a retrospective analysis of United States (US) administrative claims data that examined the association between tardive dyskinesia (TD) and potential risk factors will be presented at the annual Digestive Disease Week Meeting in San Diego, CA taking place from May 21-24, 2022. Evoke’s flagship product, GIMOTI, is an FDA-approved novel nasal formulation of metoclopramide commercially...

Continue reading

Allied Energy Corporation Retained Council To Advise On and Initiate a Corporate Up-listing and Share Buyback Program

Carrollton, Texas, Feb. 24, 2022 (GLOBE NEWSWIRE) — Allied Energy Corp (OTC Pink: AGYP), is a producing oil and gas company focused on leasing and reworking of oil and gas reserves in one of the most prolific hydrocarbon areas in the United States. Allied Energy is pleased to announce that the Company has retained the services of a securities council to assist the company “AGYP” in the process of up-listing to a recognized North American Stock Exchange, excluding the US OTCMarkets. Furthermore, council has also been secured to advise and help structure an ongoing share buyback program of AGYP’s common stock. Council retained by Allied has practiced securities law for over 30 years in North America and has successfully helped companies list and up-list their securities from lower tiered exchanges to higher tiered exchanges....

Continue reading

SFLMaven on Pace for Significant Revenue Growth in 2022 as Company Finalizes Purchase of Metaverse Real Estate

FORT LAUDERDALE, FL, Feb. 24, 2022 (GLOBE NEWSWIRE) — SFLMaven Corp. (OTC Pink: SFLM), (“SFLMaven” or the “Company”) (www.sflmaven.com), a leading provider of high-end luxury goods, is pleased to provide current and prospective shareholders with an update on performance as well as qualitative and quantitative guidance for the Company’s outlook ahead. “When we closed last year, we pointed to a number of key tailwinds driving our jewelry business that could factor into accelerating growth in 2022,” stated Joseph Ladin, CEO of SFLMaven. “So far, that seems to be playing out this year, with our Q1 performance putting us on pace for double-digit organic growth, which helps to lay a sturdy foundation as we expand into new domains, including non-fungible tokens and the Metaverse.” Management notes that the Company...

Continue reading

Vaxart’s S-Only COVID-19 Vaccine Candidate Produces Strong-Cross Reactive Mucosal and Systemic Immune Responses in Non-Human Primates

Newly published data demonstrates substantial cross-reactivity against multiple variants of COVID-19 S-only candidate is believed to be the first to demonstrate robust neutralizing antibody responses in mucosal sites, which is where primary infection occurs Vaxart’s S-only candidate induced a 1000-fold increase in nasal IgA responses to the variants, which could have substantial impact on reducing community transmission SOUTH SAN FRANCISCO, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) — A new study published on BioRxiv.org demonstrates that Vaxart’s S-only COVID-19 clinical vaccine candidate, now being studied by Vaxart in Phase II trials, generated antibodies to the original COVID-19 virus strain and to the beta, delta, alpha and gamma variants of SARS-CoV-2 in the serum and nasal mucosa of non-human primates (NHPs). The NHP results...

Continue reading

Millrock Provides Company Update

Figure 1 Alaska Project Location Map. Current projects have gold marker. Former projects have black marker.Figure 2 Project locations in which Millrock has ownership and / or royalty interests.Key Highlights – Anticipated 2022 Activity:Drilling on at least four and perhaps as many as eight projects in which Millrock has equity and royalty interests.Treasure Creek, Ester, Fairbanks district, Liberty Bell gold projects, Fairbanks area, Alaska (Felix Gold 15,000 meters planned). 64North gold project, Pogo Mine area, Alaska (Resolution Minerals, planning in progress). Apex El Nido gold project, southeast Alaska (Coeur Explorations, 1,500 meters under consideration). Batamote copper project, Sonora Mexico (Mine Discovery Fund earning in, preliminary planning in progress). El Picacho gold project, Sonora Mexico (Tocvan Ventures, preliminary...

Continue reading

Trust Stamp Launches Privacy-First Identity Orchestration Platform

Delivers security, operational efficiency, and cost benefits unmatched by traditional identity frameworks Atlanta , Feb. 24, 2022 (GLOBE NEWSWIRE) — Trust Stamp (Nasdaq: IDAI, Euronext Growth: AIID ID), the Privacy-First Identity CompanyTM providing AI-powered trust and identity services used globally across multiple sectors, announces the launch of its end-to-end Identity Orchestration Platform, which streamlines delivery and implementation of the Company’s proven technologies through a low-code approach. Trust Stamp’s powerful identity platform enables clients to transform security, privacy, and usability in digital operations with a range of leading AI-powered technologies including biometric, document and liveness verification, as well as data-protection and more, in order to support robust identity frameworks that can be established,...

Continue reading

Kinross completes acquisition of Great Bear Resources

TORONTO, Feb. 24, 2022 (GLOBE NEWSWIRE) — Kinross Gold Corporation (TSX:K; NYSE:KGC) (the “Company”) is pleased to announce today that it has completed the previously announced plan of arrangement (the “Arrangement”) to acquire all of the issued and outstanding shares of Great Bear Resources Ltd. (“Great Bear”). “The closing of the acquisition of Great Bear Resources represents a milestone for Kinross as we advance our future growth strategy. We are excited to add such a high-quality asset in a top mining jurisdiction to our global portfolio,” said J. Paul Rollinson, Kinross Gold President and CEO. “Our exploration and development strategy will start immediately, including our goal of drilling 200,000 metres this year. We aim to further define the asset’s untapped potential and unlock the significant value we see from its numerous...

Continue reading

Catalyst Pharmaceuticals Teams Up with Patients and Advocacy Groups to Ring Nasdaq Opening Bell on Rare Disease Day 2022

Ceremony Recognizes Importance of Biopharma Industry and Advocacy Group Collaboration to Address Needs for New Treatments in Orphan and Rare Disorders Together, Will Ring the Nasdaq Opening Bell to Kick-Off Rare Disease Day on February 28, 2022 CORAL GABLES, Fla., Feb. 24, 2022 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today announced that the company is standing with the National Organization for Rare Disorders (NORD), Global Genes, Muscular Dystrophy Association, Myasthenia Gravis Foundation of America, Conquer MG, and Myasthenia Gravis Association, to ring the opening bell of the Nasdaq market on international...

Continue reading

Codex DNA to Present at the Cowen 42nd Annual Healthcare Conference

SAN DIEGO, Feb. 24, 2022 (GLOBE NEWSWIRE) — Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that Todd R. Nelson, PhD, the company’s chief executive officer, will present virtually at the 42nd Annual Cowen Healthcare Conference on Wednesday, March 9th at 2:10 pm Eastern time / 11:10 am Pacific Time. Additionally, Todd will participate in a ‘Synthetic Biology Enabling Technologies Panel’ on Monday, March 7th at 10:30 am Eastern time / 7:30 am Pacific Time. The presentation and panel discussion will both be webcast live and can be accessed through a link on the investors section of Codex DNA’s website at https://ir.codexdna.com. An archived replay of each webcast will be available for 30 days following the event. About Codex DNACodex DNA is empowering scientists with the ability...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.